1840 related articles for article (PubMed ID: 33743843)
1. Free licensing of vaccines to end the COVID-19 crisis.
Bozorgmehr K; Jahn R; Stuckler D; McKee M
Lancet; 2021 Apr; 397(10281):1261-1262. PubMed ID: 33743843
[No Abstract] [Full Text] [Related]
2. It's time to consider a patent reprieve for COVID vaccines.
Nature; 2021 Apr; 592(7852):7. PubMed ID: 33785920
[No Abstract] [Full Text] [Related]
3. Time is running out for COVID vaccine patent waivers.
Nature; 2022 Mar; 603(7903):764. PubMed ID: 35352056
[No Abstract] [Full Text] [Related]
4. A patent waiver on COVID vaccines is right and fair.
Nature; 2021 May; 593(7860):478. PubMed ID: 34035532
[No Abstract] [Full Text] [Related]
5. Omicron is bad but the global response is worse.
Nature; 2021 Dec; 600(7888):190. PubMed ID: 34876667
[No Abstract] [Full Text] [Related]
6. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
Gillat A
Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
[No Abstract] [Full Text] [Related]
7. von der Leyen admits to COVID-19 vaccine failures.
Hyde R
Lancet; 2021 Feb; 397(10275):655-656. PubMed ID: 33610198
[No Abstract] [Full Text] [Related]
8. Pool patents to get COVID vaccines and drugs to all.
Billette de Villemeur E; Dequiedt V; Versaevel B
Nature; 2021 Mar; 591(7851):529. PubMed ID: 33742180
[No Abstract] [Full Text] [Related]
9. Is there light at the end of the Covid-19 tunnel?
Mortimer PP
Rev Med Virol; 2021 May; 31(3):e2173. PubMed ID: 33002254
[No Abstract] [Full Text] [Related]
10. COVID-19 Vaccine: Practical Clinical Considerations.
Laine C; Cotton D; Moyer DV
Ann Intern Med; 2021 May; 174(5):694. PubMed ID: 33769829
[TBL] [Abstract][Full Text] [Related]
11. Sharing Technology and Vaccine Doses to Address Global Vaccine Inequity and End the COVID-19 Pandemic.
Kavanagh MM; Gostin LO; Sunder M
JAMA; 2021 Jul; 326(3):219-220. PubMed ID: 34196659
[No Abstract] [Full Text] [Related]
12. The race to make a COVID-19 vaccine.
Boseley S
Lancet; 2021 Sep; 398(10303):832-833. PubMed ID: 34481566
[No Abstract] [Full Text] [Related]
13. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
14. Anticipating Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Testing, Licensure, and Recommendations for Use.
Edwards KM; Orenstein WA
J Pediatr; 2020 Sep; 224():124-128. PubMed ID: 32565096
[No Abstract] [Full Text] [Related]
15. To curb COVID-19, global health must go local.
Nat Med; 2021 Jun; 27(6):929. PubMed ID: 34031608
[TBL] [Abstract][Full Text] [Related]
16. The case for compulsory licensing during COVID-19.
Wong H
J Glob Health; 2020 Jun; 10(1):010358. PubMed ID: 32509289
[No Abstract] [Full Text] [Related]
17. COVID-19 vaccines approved in the European Union: current evidence and perspectives.
Bellino S
Expert Rev Vaccines; 2021 Oct; 20(10):1195-1199. PubMed ID: 34338126
[No Abstract] [Full Text] [Related]
18. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
19. COVID-vaccine results are on the way - and scientists' concerns are growing.
Mallapaty S; Ledford H
Nature; 2020 Oct; 586(7827):16-17. PubMed ID: 32978611
[No Abstract] [Full Text] [Related]
20. A network analysis of COVID-19 mRNA vaccine patents.
Gaviria M; Kilic B
Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
